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Abstract
Background: Frizzled 3 (Fzd3) is a receptor required for the Wnt-signaling pathway, which has been implicated in the
development of the central nervous system, including synaptogenesis and structural plasticity. We previously found a
significant association between the FZD3 gene and susceptibility to schizophrenia, but subsequent studies showed
inconsistent findings. To understand the roles of the FZD3 gene in psychotic disorders further, it should be useful to
examine FZD3 in patients with methamphetamine psychosis because the clinical features of methamphetamine psychosis
are similar to those of schizophrenia.
Methods: Six SNPs of FZD3, rs3757888 in the 3' flanking region, rs960914 in the intron 3, rs2241802, a synonymous
SNP in the exon5, rs2323019 and rs352203 in the intron 5, and rs880481 in the intron 7, were selected based on the
previous schizophrenic studies and analyzed in 188 patients with methamphetamine psychosis and 240 age- and gender-
matched controls.
Results: A case-control association analyses revealed that two kinds of FZD3 haplotypes showed strong associations
with methamphetamine psychosis (p < 0.00001). Having the G-A-T-G or A-G-C-A haplotype of rs2241802-rs2323019-
rs352203-rs880481 was a potent negative risk factor (odds ratios were 0.13 and 0.086, respectively) for
methamphetamine psychosis.
Conclusion: Our present and previous findings indicate that genetic variants of the FZD3 gene affect susceptibility to
two analogous but distinct dopamine-related psychoses, endogenous and substance-induced psychosis.
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Background
The neurodevelopmental hypothesis of schizophrenia
suggests that interaction between genetic and environ-
mental events occurring during critical early periods of
neuronal growth may negatively influence the way by
which nerve cells are laid down, differentiated, selectively
culled by apoptosis and remodeled by expansion and
retraction of dendrites and synaptic connections [1,2].
The Wnt family molecules play several roles in neuronal
development by inducing cells to proliferate, differentiate,
and survive [3,4]. In particular, Wnt signaling plays roles
in regulating patterning during cortical development,
axon remodeling, synaptic differentiation, clustering of
synapsin I at presynaptic terminals [5-7] and the cytoar-
chitectural derangement that was observed in the brains
of schizophrenics [8]. A mutation in the Wnt1 gene, one
of the Wnt family genes, leads to abnormal cerebral devel-
opment in mice [9], and mice deficient in Frizzled 3
(Fzd3), a receptor of Wnt ligands, showed loss of tha-
lamo-cortical tracts and defects in corpus callosum devel-
opment, abnormalities which were reported in
schizophrenic patients [10-12]. Therefore, alteration of
the Wnt/Fzd cascade may represent an aberrant neurode-
velopment involved in schizophrenia [13].
Fzd3 is a required receptor in the Wnt-signaling pathway.
In 2003, we reported a significant association between the
gene encoding Fzd3 (FZD3) and susceptibility to schizo-
phrenia [14]. Subsequent studies tried to replicate our
findings, but the results were inconsistent. Yang et al. [15]
revealed a significant association of the FZD3 gene with
schizophrenia in Han Chinese populations by a transmis-
sion disequilibrium test, and Zhang et al. [16] also found
a significant association by a family-based case-control
study. On the other hand, several studies failed to find sig-
nificant evidence of a genetic effect of the FZD3 gene on
schizophrenia [17-19]. The inconsistencies in genetic
studies in the relationship of the FZD3 gene with schizo-
phrenia may suggest heterogeneity of schizophrenia and a
requirement for further studies using larger sample size.
We consider that it may be also useful to investigate the
role of the FZD3 gene in other types of psychotic disorders
for better understanding of the physiological roles of Fzd3
and the Wnt cascade in schizophrenia or psychotic condi-
tions.
Repeated abuse of methamphetamine frequently predis-
poses to psychotic conditions. The clinical similarity
between methamphetamine psychosis and schizophrenia
has been pointed out, and methamphetamine psychosis
has been considered to be a pharmacological model of
schizophrenia, especially the paranoid subtype [20-22].
Thus, methamphetamine psychosis and schizophrenia
resemble each other in a cross-section of clinical features,
e.g., auditory hallucination and delusion, the longitudi-
nal process of progressive exacerbation with acute
relapses, good response to neuroleptics, and enduring vul-
nerability to relapse under stressors. Enhanced dopamine
release in the striatum due to a challenge dose of metham-
phetamine was observed in schizophrenic patients and
methamphetamine-sensitized rats, an animal model of
methamphetamine psychosis [23-25]. These similarities
between schizophrenia and methamphetamine psychosis
in both symptomatology and pharmacological aspects
may suggest that shared neural mechanisms are involved
in both psychotic disorders. Therefore, in order to exam-
ine the roles of Fzd3 in mechanisms underlying the devel-
opment of psychosis, we analyzed the FZD3  gene in
patients with methamphetamine psychosis.
Methods
Subjects
The subjects consisted of 188 patients with methamphet-
amine psychosis (158 male, 30 female; mean age ± SD,
36.6 ± 11.8) and 240 age-, gender-, and geographical ori-
gin-matched healthy controls (192 male, 48 female; mean
age ± SD, 36.6 ± 10.6), who have no individual or family
history of drug dependence or major psychotic disorders
such as schizophrenia and bipolar disorders. All the sub-
jects were unrelated Japanese, born and living in relatively
restricted areas of Japan, northern Kyushu, Setouchi, Chu-
kyo, Tokai, and Kanto. All subjects were out-patients or
inpatients in psychiatric hospitals of the Japanese Genet-
ics Initiative for Drug Abuse (JGIDA), a multicenter col-
laborative study group. Consensus diagnoses of
methamphetamine psychosis were made by two trained
psychiatrists according to the ICD-10 criteria on the basis
of interviews and medical records. The patients with
methamphetamine psychosis in the present study usually
showed predominant positive symptoms such as delusion
and hallucination. We excluded cases in which the pre-
dominant symptoms were of the negative and/or disor-
ganized type in order to maintain the homogeneity of the
patient group. The study protocol and purpose were
explained to all subjects participating in the study, and
written informed consent was obtained from all subjects.
This study was approved by the Ethics Committee of each
participating institute of JGIDA.
DNA analysis
We genotyped the three single nucleotide polymorphisms
(SNPs), rs3757888 (SNP1) in the 3' flanking region,
rs960914 (SNP2) in the intron 3, and rs2241802 (SNP3),
a synonymous SNP in the exon5 of the FZD3 gene that
were analyzed in our previous study [14]. We also ana-
lyzed three additional SNPs, rs2323019 (SNP4) and
rs352203 (SNP5) in the intron 5, and rs880481 (SNP6) in
the intron 7 of the gene because a significant association
with schizophrenia was reported by Yang et al. [15] and
Zhang et al. [16]. Genotyping was performed by the PCR-Behavioral and Brain Functions 2008, 4:37 http://www.behavioralandbrainfunctions.com/content/4/1/37
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RFLP method. The genomic DNA was extracted from
peripheral leukocytes using phenol-chloroform. Each pol-
ymorphic site was amplified by PCR (PCR primer
sequence of each SNP is available on request) in a 15-μl
volume containing 3% dimethyl sulfoxide and 0.75 units
of Taq DNA polymerase (Promega Co., Japan) using a
unique primer set. PCR reaction was performed under the
following conditions: 95°C for 5 min, then 35 cycles of 30
s of denaturing at 95°C, 1 min of annealing at the appro-
priate temperature, and 30 s of extension, and final elon-
gation at 72°C for 10 min. The PCR products were
digested with the corresponding restriction enzyme for
each polymorphism, DdeI  for rs3757888, RsaI  for
rs960914, AluI for rs2241802, SspI for rs2323019, NlaIII
for rs352203, Eco32I  for rs880481, and then electro-
phoresed on 3.0% agarose gels and stained with GelStar
(TaKaRa Co., Japan). All genotyping was performed in a
blinded fashion, with the control and cases samples
mixed randomly. The genotyping of the SNPs were con-
firmed in part by direct sequencing or a TaqMan SNP gen-
otyping assay (Applied Biosystems, Foster City, CA,
U.SA.).
Statistical analysis
Statistical analysis of association was performed using
SNPAlyze software (Dynacom Co., Japan). Deviation
from Hardy-Weinberg equilibrium and case- control
study were tested using the χ2 test for goodness of fit and
χ2 test for dependence, respectively. Linkage disequilib-
rium (LD) was tested using the χ2 test, and D' and r2 values
were made the index in the authorization of LD. Case-
control haplotype analysis was performed by the permu-
tation method, and permutation p-values were calculated
based on 100,000 replications.
Results
The genotype distribution and allele frequencies of the
each polymorphism are shown in Table 1. The genotype
distributions of patients and control subjects did not devi-
ate from Hardy-Weinberg equilibrium at any SNP exam-
ined. The allele frequencies of SNP1, SNP2, and SNP3
Table 1: Genotype and allele distribution of six SNPs of the FZD3 gene in controls and patients with methamphetamine (MAP) 
psychosis
Genotype p Allele p
SNP1 rs3757888 N A/A A/G G/G A G
Control 230 198(86.1) 31(13.5) 1(0.4) 427(92.8) 33(7.2)
MAP Psychosis 186 151(81.2) 32(7.2) 3(1.61) 0.26 334(89.8) 38(10.2) 0.19
SNP2 rs960914 N T/T T/C C/C T C
Control 240 67(27.9) 130(54.2) 43(17.9) 264(55.0) 216(45.0)
MAP Psychosis 185 45(24.3) 103(55.7) 37(20.0) 0.66 193(52.2) 177(47.8) 0.41
SNP3 rs2241802 N A/A A/G G/G A G
Control 240 49(20.4) 124(51.7) 67(27.9) 222(46.2) 258(53.8)
MAP Psychosis 181 44(24.3) 97(53.6) 40(22.1) 0.34 185(51.1) 177(48.9) 0.16
SNP4 rs2323019 N A/A A/G G/G A G
Control 239 72(31.4) 113(49.3) 44(19.2) 257(56.1) 201(43.9)
MAP Psychosis 186 45(24.1) 101(54.0) 41(21.9) 0.25 191((51.1) 183(48.9) 0.15
SNP5 rs352203 N T/T T/C C/C T C
Control 192 64(33.3) 98(51.1) 30(15.6) 226(58.9) 158(41.1)
MAP Psychosis 176 49(27.8) 98(55.7) 29(16.5) 0.52 196(55.7) 156(44.3) 0.38
SNP6 rs880481 N A/A A/G G/G A G
Control 236 43(18.2) 123(52.1) 70(29.7) 209(44.3) 263(55.7)
MAP Psychosis 186 30(16.1) 103(55.4) 53(28.5) 0.97 163(43.8) 209(56.2) 0.99
SNP, Single nucleotide polymorphism.
Numbers in parentheses indicate percentages.Behavioral and Brain Functions 2008, 4:37 http://www.behavioralandbrainfunctions.com/content/4/1/37
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were approximately same as those of our previous study
[14]. The allele frequencies of SNP4, SNP5, and SNP6 in
the present study also showed values similar to those of
previous studies of Japanese and Chinese populations
[16-18].
We found no significant difference between patients and
controls in the frequencies of the genotype or allele at any
single SNP of the FZD3 gene. We estimated the pairwise
LD between the six SNPs of the FZD3 gene using the D'
and r2values as an index (Table 2). A D' range of 0.7–0.9
and a r2 > 0.3 were found between SNP2, SNP3, SNP4,
SNP5, and SNP6, but not between SNP1 and the other
SNPs. This suggests that SNP2, SNP3, SNP4, SNP5, and
SNP6 are in linkage disequilibrium and located within
one LD block. Then, we performed case-control haplotype
analysis using SNP2 to SNP6 (Table 3). Haplotype analy-
ses revealed significant differences in patients and control
subjects at SNP5-6, SNP4-5-6, SNP3-4-5-6, and SNP2-3-4-
5-6, but not at SNP2-3, SNP3-4, SNP4-5, SNP2-3-4, SNP3-
4-5, or SNP2-3-4-5. The largest χ2 and smallest permuta-
tion P  values were found in the haplotype analysis of
SNP3-4-5-6 (χ2 = 64.8, permutation p < 0.00001). The
estimated individual haplotypic frequencies of SNP3-4-5-
6 are shown in Table 4. Eight kinds of haplotypes consist-
ing of SNP3-4-5-6 with more than 1% overall frequency
were identified. The estimated haplotype frequency of G-
A-T-G and A-G-C-A of SNP3-4-5-6 were significantly
lower in patients with methamphetamine psychosis than
in controls (p < 0.00001 and p = 0.0003, respectively).
Conversely, the A-G-C-G haplotype was significantly in
excess in patients compared with controls (p = 0.0246). To
avoid a type I error due to multiple comparison, Bonfer-
roni's correction was applied to the results. G-A-T-G and
A-G-C-A haplotypes were still significantly less frequent in
the methamphetamine patients than in the controls, but
A-G-C-G was not significantly different between the
groups after correction. The odds ratios G-A-T-G and A-G-
C-A haplotypes were 0.13 (95%CI; 0.043–0.36) and
0.086 (95%CI; 0.011–0.67), respectively. Accordingly, G-
A-T-G and A-G-C-A haplotypes of SNP3-4-5-6 were nega-
tive risk haplotypes for methamphetamine psychosis.
Discussion
We revealed that the FZD3 gene is significantly associated
with the vulnerability to psychosis induced by metham-
phetamine abuse, and two haplotypes of the FZD3 gene
comprising SNP3-4-5-6 (rs2241802-rs2323019-
rs352203-rs880481) were identified as potent negative
risk factors for methamphetamine psychosis. The G-A-T-G
and A-G-C-A haplotypes potently reduce the risks of pre-
disposition to psychosis after methamphetamine abuse to
one seventh to one eleventh. In our previous study of
schizophrenia [14], distribution of the SNP2 genotypes
and haplotypes comprising SNP2-SNP3 was significantly
associated with schizophrenia. Zhang et al. [16] reported
that the haplotype comprising SNP4-SNP5-SNP6 was
associated with schizophrenia in a Chinese population.
These findings indicate that genetic variants of the FZD3
gene may affect susceptibility to two analogous but dis-
tinct psychoses, endogenous psychosis of schizophrenia
and substance-induced psychosis. This may imply that
Fzd3 is involved in a liability to psychotic symptoms such
as hallucination and delusion irrespective of whether they
are due to schizophrenia or methamphetamine psychosis.
Dopamine is a key molecule in the pathophysiology of
both schizophrenia and methamphetamine psychosis.
Enhanced dopamine release in the terminals of mesolim-
bic dopamine projections was demonstrated in vivo in
patients with schizophrenia, and the amount of the
increase in dopamine was positively associated with the
emergence or worsening of psychotic symptoms [25].
Similar phenomena were demonstrated in mesolimbic
and mesocortical terminals in animal models of metham-
phetamine psychosis [23]. Wnt1 was found to be
expressed in close vicinity to developing midbrain
dopamine neurons, which are the origins of the mesolim-
bic and mesocortical dopamine pathways. Wnt1 regulates
the genetic network leading to establishment of the mid-
brain progenitor domain in the ventral midbrain during
embryonic development and of the subsequent terminal
differentiation of midbrain dopamine neurons [26,27]. It
is possible that differences in Wnt signaling due to genetic
variants of the FZD3  gene affect the development of
dopamine neurons of the mesolimbic or mesocortical
pathway in early brain development and susceptibility to
these two dopamine-related psychoses in adulthood.
Another molecule that potentially links Fzd3 and these
two related psychoses is glycogen synthesis kinase-3
(GSK-3), a serine/threonine kinase that is a downstream
component of the Wnt/Fzd cascades. Binding of Wnt lig-
ands to Fzd family receptors leads to activation of the
intracellular protein disheveled, which inactivates GSK-
Table 2: Pairwise Linkage Disequilibrium between six SNPs of 
the FZD3 gene
SNP1 SNP2 SNP3 SNP4 SNP5 SNP6
SNP1 0.840 0.557 0.379 0.853 0.706
SNP2 0.057 0.760 0.915 0.970 0.749
SNP3 0.031 0.532 0.834 0.831 0.729
SNP4 0.012 0.829 0.627 0.982 0.760
SNP5 0.052 0.841 0.542 0.843 0.788
SNP6 0.036 0.377 0.389 0.387 0.367
Linkage disequilibrium was tested using χ2 test. Upper right and lower 
left diagonals show D' and r-square values, respectively. D'>0.7 and r-
square>0.3 were shown in bold.Behavioral and Brain Functions 2008, 4:37 http://www.behavioralandbrainfunctions.com/content/4/1/37
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3β. This in turn leads to the stabilization and accumula-
tion of β-catenin, which translocates to the nucleus where
it interacts with nuclear transcription factors for the genes
involved in neuronal development. Briefly, GSK-3β medi-
ates Wnt/Fzd signaling cascades. Dysregulation of GSK-3β
and 3α is one of promising neurodevelopmental hypoth-
eses of schizophrenia [13,28]. GSK-3 is also regulated by
dopamine signaling through protein kinase B [29]. Sev-
eral studies showed, but not consistently, that GSK-3 pro-
tein levels and activities are altered in schizophrenic
brains [30,31] and lymphocytes [32,33]. Several genes,
e.g.,  DISC1  and  NRG1, which have been repeatedly
shown to be associated with susceptibility to schizophre-
nia, are involved in GSK-3/Wnt regulatory pathways [28].
Recently, the gene encoding DKK4, a component of the
GSK-3/Wnt signaling cascade, was shown to be associated
with schizophrenia. DKK4 inhibits Wnt-Fzd binding,
resulting in inactivation of GSK-3 [34]. On the other
hand, amphetamine also affects GSK-3 activity. Adminis-
tration of amphetamine to mice increased Ser9 phospho-
rylation of GSK-3β, resulting in a reduction of its activity
in the frontal cortex and striatum [35], and GSK-3 gene
knockdown mice showed a reduced response to amphet-
amine [36]. Intriguingly, psychotomimetics of two differ-
ent classes, phencyclidine and D-lysergic acid, also had
the same effects on GSK-3β, which may imply that sub-
stance-induced psychosis might be the result of a reduc-
tion in GSK-3 signaling. In contrast, chronic treatment
with typical and atypical neuroleptics that ameliorate the
psychotic symptoms of schizophrenia and methampheta-
mine psychosis increase the levels and activities of GSK-3
[37]. It was also found that chronic neuroleptic treatment
increased  β-catenin in the ventral midbrain, whereas
amphetamine decreased it [38]. These findings indicate
that the altered GSK-3/Wnt signaling is involved in liabil-
ity to expression of positive psychotic symptoms such as
the hallucinations and delusions in patients suffering
from both schizophrenia and methamphetamine-
induced psychosis. This hypothesis may be supported by
our present and previous findings because the FZD3 gene
was significantly associated with not only schizophrenia
but also methamphetamine psychosis.
The present results were still significant even after a Bon-
ferroni correction, although it is possibly a chance finding
due to less power. The power analysis showed that our
Table 3: Haplotype analysis of the FZD3 gene
1SNP 2SNP 3SNP 4SNP 5SNP











Haplotype analysis was performed by permutaion method. Bold values represent significant p values.
Table 4: Haplotype frequencies from positive permutation analyses
Haplotype Frequency Permutation p-values Odds ratio (95%CI)
(SNP3-4-5-6) Controls MAP Psychosis
G-A-T-A 0.3523 0.4148 0.0889
A-G-C-G 0.3178 0.3970 0.0246 1.42 (1.14–1.76)
G-A-T-G 0.1542 0.0243 <0.00001 0.13 (0.07–0.22)
A-A-T-G 0.0382 0.0635 0.1283
A-G-C-A 0.0625 0.0070 0.0003 0.086 (0.03–0.24)
A-G-T-G 0.0211 0.0354 0.2791
G-G-C-G 0.0196 0.0379 0.1678
A-A-T-A 0.0169 0.0090 0.4565
Haplotypes with overall frequencies are less than 1% were eliminated.Behavioral and Brain Functions 2008, 4:37 http://www.behavioralandbrainfunctions.com/content/4/1/37
Page 6 of 7
(page number not for citation purposes)
present sample size had more than 80% power to detect a
significant difference at 0.05 of any SNP examined, but it
must have less power for haplotype analyses. Therefore,
our findings should be confirmed in studies using a larger
number of subjects and different populations. It may also
be useful for further investigation of the roles of Fzd3 in
psychoses to examine the genetic association of the FZD3
gene with other types of psychoses, e.g., cocaine-induced
paranoia or delusional type of bipolar disorders.
Conclusion
We examined genetic association of FZD3 and found that
two kinds of FZD3 haplotypes showed strong associations
with methamphetamine psychosis. Having the G-A-T-G
or A-G-C-A haplotype of rs2241802-rs2323019-
rs352203-rs880481 was a potent negative risk factor
(odds ratios were 0.13 (95%CI; 0.07–0.22) and 0.086
(0.03–0.24), respectively) for methamphetamine psycho-
sis. Our present and previous findings indicate that
genetic variants of the FZD3 gene affect susceptibility to
two analogous but distinct dopamine-related psychoses,
endogenous and substance-induced psychosis.
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